Written & Oral Exam
To be eligible for subspecialty certification in Otolaryngic Allergy, candidates must meet the criteria below:
- Have their residency documented “program complete” status by the AOCOO-HNS.
- Have completed one year of AOA-approved training in Otolaryngic Allergy. This may consist of a two- or three-year interrupted post-residency fellowship.
- Be certified by this Board in Otolaryngology or Otolaryngology/Facial Plastic Surgery.
- Hold an unrestricted license to practice in a state or territory.
- Adhere to the AOA Code of Ethics.
- Meet AOA board eligibility requirements.
At the time of application, you must submit the following to the AOBOO-HNS:
- A copy of your certification.
- Copies of CME certificates showing 90 CME credits earned in the last five years, 30 of which must be obtained through a Basic Course in Otolaryngic Allergy.
- Completed application form, fee and five clinical case studies, one of which must be a food allergy case.
- Copy of your current state medical license.
An exam fee of $2,000 must accompany your completed application. No application will be considered complete until all fees have been paid.
If an applicant fails the exam, the fee for re-examination is $2,000.
Exam Dates and Deadlines
The Otolaryngic Allergy certification exam is offered once per year, in the spring. The application period opens in the fall. Applications start at the end of November and close in March.
Exam Content Outline
The Otolaryngic Allergy certification exam has two sections: a written section and an oral section. The written exam consists of 100 multiple-choice questions covering all aspects of Otolaryngic Allergy including basic science, immunology, clinical performance, testing, and desensitization.
The oral section consists of case studies as prescribed by the Board. Case studies must reflect techniques and methodologies that adhere to approved methods. They must adhere to accepted policies regarding set testing, in vitro testing and food testing.
Cases must be from the past two years. Treatment may consist of avoidance, chemotherapy, and/or immunotherapy. Documentation must include diagnosis, therapy, protocol and response. Patients must have been followed for at least six months.